Advertisement

Der Urologe

, Volume 56, Issue 2, pp 217–223 | Cite as

Kortikoide im Management des fortgeschrittenen Prostatakarzinoms

  • H. KüblerEmail author
Übersichten

Zusammenfassung

Kortikosteroide haben seit Jahrzehnten einen festen Stellenwert in der Onkologie, v. a. aufgrund ihrer entzündungshemmenden Wirkung. Speziell beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) kommen Kortikoide sowohl zur Linderung tumorbedingter Symptome – insbesondere bei Schmerzen durch Knochenmetastasen – als auch zum Nebenwirkungsmanagement etablierter Substanzen wie Docetaxel, Cabazitaxel und Abirateronacetat zum Einsatz. Im Zusammenhang mit Abirateronacetat verhindern niedrig dosierte Kortikoide (Prednison oder Prednisolon) die mineralokortikoidbedingten Nebenwirkungen von Abirateron. Darüber hinaus können Kortikoide selbst über direkte Antitumoreffekte mit einem Abfall der PSA-Werte assoziiert sein.

Schlüsselwörter

Prostatakarzinom, metastasiertes Kastrationsresistenz Kortikosteroide Palliation Antitumoreffekte Abirateronacetat Chemotherapie 

Corticosteroids in the management of advanced prostate cancer

Abstract

Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone. In addition, corticosteroids may exert direct antitumoral activities, resulting in PSA decline.

Keywords

Prostate cancer, metastatic Castration-resistance Corticosteroids Palliation Antitumor effects Abiraterone acetate Chemotherapy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

H. Kübler gibt Referenten- und Beratertätigkeit für die Firmen Astellas Pharma, Janssen-Cilag und Sanofi-Aventis an.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut (2013) Krebs in Deutschland 2009–2010, Häufigkeiten und Trends: 9. Ausgabe. Robert Koch-Institut, BerlinGoogle Scholar
  2. 2.
    Ryan CJ et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160CrossRefPubMedGoogle Scholar
  3. 3.
    Scher HI et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197CrossRefPubMedGoogle Scholar
  4. 4.
    Parker C et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223CrossRefPubMedGoogle Scholar
  5. 5.
    de Bono JS et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154CrossRefPubMedGoogle Scholar
  6. 6.
    Thiel H, Roewer N (Hrsg) (2009) Anästhesiologische Pharmakotherapie. Thieme-Verlag, StuttgartGoogle Scholar
  7. 7.
    Nagata K et al (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47(4):656–664CrossRefPubMedGoogle Scholar
  8. 8.
    Mirshahi M et al (1996) The mineralocorticoid hormone receptor and action in the eye. Biochem Biophys Res Commun 219(1):150–156CrossRefPubMedGoogle Scholar
  9. 9.
    Coirini H et al (1985) Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro. Brain Res 361(1–2):212–216CrossRefPubMedGoogle Scholar
  10. 10.
    Arora VK et al (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309–1322CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Fachinformation Zytiga®, Stand Juni 2015Google Scholar
  12. 12.
    Fachinformation Taxotere®, Stand Mai 2015Google Scholar
  13. 13.
    Fachinformation Jevtana®, Stand April 2016Google Scholar
  14. 14.
    Dorff TB, Crawford ED (2013) Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol 24(1):31–38CrossRefPubMedGoogle Scholar
  15. 15.
    Ndibe C et al (2015) Corticosteroids in the management of prostate cancer: a critical review. Curr Treat Options Oncol 16(2):6CrossRefPubMedGoogle Scholar
  16. 16.
    Ellis J et al (2015) Corticosteroid use in mCRPC patients treated with abiraterone or enzalutamide using real world data from three databases. J Clin Oncol 33(Suppl):abstr e16071Google Scholar
  17. 17.
    Loriot Y et al (2015) Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 16(5):509–521CrossRefPubMedGoogle Scholar
  18. 18.
    Scher HI et al (2012) Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Ann Oncol 23(Suppl 9):Abstr 899DGoogle Scholar
  19. 19.
    Scher HI et al (2013) Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol 31(Suppl 6):Abstr 6Google Scholar
  20. 20.
    Venkitaraman R et al (2013) A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. J Clin Oncol 6(Suppl):Abstr 123Google Scholar
  21. 21.
    Venkitaraman R et al (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101:440–443PubMedGoogle Scholar
  22. 22.
    Storlie JA et al (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76:96–100CrossRefPubMedGoogle Scholar
  23. 23.
    Nishimura K et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570–2576CrossRefPubMedGoogle Scholar
  24. 24.
    Saika T et al (2001) Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol 8:290–294CrossRefPubMedGoogle Scholar
  25. 25.
    Sartor O et al (1998) Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52:252–256CrossRefPubMedGoogle Scholar
  26. 26.
    Fizazi K et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992CrossRefPubMedGoogle Scholar
  27. 27.
    Fizazi K et al (2015) Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts). J Clin Oncol 33(Suppl 7):abstr 169Google Scholar
  28. 28.
    Tannock I et al (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7(5):590–597PubMedGoogle Scholar
  29. 29.
    Bruera E et al (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69(7–8):751–754PubMedGoogle Scholar
  30. 30.
    Hanks GW et al (1983) Corticosteroids in terminal cancer – a prospective analysis of current practice. Postgrad Med J 59(697):702–706CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    NCCN (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): adult cancer pain, version 2. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Zugegriffen: 24. Nov. 2015Google Scholar
  32. 32.
    NCCN (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): cancer-related fatigue, version 2. http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf. Zugegriffen: 24. Nov. 2015Google Scholar
  33. 33.
    NCCN (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): antiemesis, version 2. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Zugegriffen: 24. Nov. 2015Google Scholar
  34. 34.
    Hiddemann W, Huber H, Bartram C (Hrsg) (2004) Die Onkologie – Teil 1. Springer, Berlin HeidelbergGoogle Scholar
  35. 35.
    Langston B et al (2013) The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer 21(6):1761–1771CrossRefPubMedGoogle Scholar
  36. 36.
    Hofman M et al (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl 1):4–10CrossRefPubMedGoogle Scholar
  37. 37.
    Glaus A et al (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Eur J Cancer Care 2(Suppl):8–23CrossRefGoogle Scholar
  38. 38.
    Fachinformation Xtandi™, Stand Mai 2015Google Scholar
  39. 39.
    Sternberg CN et al (2013) Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 24(4):1017–1025CrossRefPubMedGoogle Scholar
  40. 40.
    Logothetis C et al (2011) Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. J Clin Oncol 29(Suppl):abstr 4520Google Scholar
  41. 41.
    Naim AB et al (2014) Examining experiences of patients currently being treated with abiraterone acetate (AA) for metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol 32(Suppl):abstr e16102Google Scholar
  42. 42.
    Attard G et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563–4571CrossRefPubMedGoogle Scholar
  43. 43.
    Venkitaraman R et al (2015) A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67(4):673–679CrossRefPubMedGoogle Scholar
  44. 44.
    Lorente D et al (2014) Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 111(12):2248–2253CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Diederich S et al (2004) Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Horm Metab Res 36(6):423–429CrossRefPubMedGoogle Scholar
  46. 46.
    ClinicalTrials.gov (2013) Abiraterone with different steroid regimens for side effect related to mineralcorticoid excess prevention in prostate cancer prior to chemotherapy. https://clinicaltrials.gov/show/NCT01867710. Zugegriffen: 18. Nov. 2015Google Scholar
  47. 47.
    Attard G et al (2016) A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). J Clin Oncol 34(suppl 2S):abstr 261Google Scholar
  48. 48.
    Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168(6):2439–2443Google Scholar
  49. 49.
    Tannock IF et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764Google Scholar
  50. 50.
    Fosså SD, Jacobsen A-B, Ginman C, Jacobsen IN, Overn S, Iversen JR, Urnes T, Dahl AA, Veenstra M, Sandstad B (2007) Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 52(6):1691–1699Google Scholar
  51. 51.
    de Bono JS et al (2011) Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 364(21):1995–2005Google Scholar
  52. 52.
    Fossa SD et al (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19(1):62–71Google Scholar
  53. 53.
    Sternberg CN et al (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncol 68(1):2–9Google Scholar
  54. 54.
    Kantoff PW et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17(8):2506–2513Google Scholar
  55. 55.
    Storlie JA et al (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76 (1):96–100Google Scholar
  56. 56.
    Morioka M et al (2002) Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int 68(1):10–15Google Scholar
  57. 57.
    Venkitaraman R et al (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101(4):440–443Google Scholar
  58. 58.
    Shamash J et al (2011) A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol. Brit J Cancer 104(4):620–628Google Scholar

Copyright information

© Springer Medizin Verlag Berlin 2016

Authors and Affiliations

  1. 1.Urologische Klinik und Poliklinik, Klinikum rechts der IsarTechnische Universität MünchenMünchenDeutschland

Personalised recommendations